BOSTON, May 13, 2021 /PRNewswire/ -- Stealth
BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of novel therapies for diseases involving mitochondrial
dysfunction, today announced that Reenie
McCarthy, CEO, will present at the following upcoming
virtual investor conferences in May:
Oppenheimer's Rare & Orphan Disease Summit
Date:
Friday, May 21, 2021
Time: 9:55 – 10:35 a.m. ET
UBS Global Healthcare Virtual Conference
Date:
Wednesday, May 26, 2021
Time: 10:00 – 10:45 a.m. ET
A live audio webcast of the presentations will be available on
the Investors & News section of Stealth's website
at https://investor.stealthbt.com/. A replay of the webcasts
will be archived on Stealth's website for 30 days following the
event.
About Stealth
We are a clinical-stage biotechnology company focused on the
discovery, development, and commercialization of novel therapies
for diseases involving mitochondrial dysfunction. Mitochondria,
found in nearly every cell in the body, are the body's main source
of energy production and are critical for normal organ function.
Dysfunctional mitochondria characterize a number of rare genetic
diseases and are involved in many common age-related diseases,
typically involving organ systems with high energy demands such as
the heart, the eye, and the brain. We believe our lead product
candidate, elamipretide, has the potential to treat both rare
metabolic cardiomyopathies, such as Barth, Duchenne muscular
dystrophy and Friedreich's ataxia, rare mitochondrial diseases
entailing nuclear DNA mutations, as well as ophthalmic diseases
entailing mitochondrial dysfunction, such as dry age-related
macular degeneration and Leber's hereditary optic neuropathy. We
are evaluating our second-generation clinical-stage candidate,
SBT-272, and our new series of small molecules, SBT-550, for rare
neurological disease indications following promising preclinical
data. We have optimized our discovery platform to identify novel
mitochondria-targeted compounds which may be nominated as
therapeutic product candidates or utilized as mitochondria-targeted
vectors to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-may-301291274.html
SOURCE Stealth BioTherapeutics Inc.